Molecular Diagnostics In Pharmacogenomics Market Size, Share & Trends Analysis Report By Product (Kits & Assays, Reagents, Services), By Therapeutic Area, By Technology, By Region, And Segment Forecasts, 2025

The global molecular diagnostics in pharmacogenomics market size was estimated at USD 699.7 million in 2024 and is projected to reach USD 1, 256.38 million in 2033, growing at a CAGR of 6.84% from 2025 to 2033. This market focuses on rapid and precise genetic testing that enables tailored drug therapy, improving clinical outcomes and reducing adverse drug reactions.

Molecular diagnostics play a central role in identifying patient-specific genetic variations and are widely adopted in areas such as oncology, cardiovascular conditions, infectious diseases, and neurological disorders. Product offerings within the market span across kits, reagents, and specialized testing services, each addressing different stages of pharmacogenomic workflows. Kits and reagents are widely used in clinical laboratories and research institutions for routine and specialized assays. Services are expanding in relevance due to the need for comprehensive interpretation, bioinformatics support, and regulatory-compliant testing. The oncology segment dominates the therapeutic landscape, with lung, breast, and colorectal cancers accounting for significant test volumes, while emerging interest is observed in neurological and immunological disorders.

In terms of technology, polymerase chain reaction (PCR) remains the most widely used method due to its cost-effectiveness and speed. Sequencing technologies, particularly next-generation sequencing (NGS), are gaining ground for their ability to analyze multiple genes simultaneously. Microarrays and other methods like electrophoresis and nucleic acid amplification techniques also contribute to the testing ecosystem. Continuous innovation, along with rising awareness of gene-drug interactions and expanding access to genomic services globally, is expected to reinforce the growth of this market over the forecast period.

Moreover, at AAN's Annual Meeting in April 2025, leading neurologists underscored the emergent role of pharmacogenomics in neurology. By focusing on genetic drivers across diseases like Alzheimer's, Parkinson's, stroke, migraine, and multiple sclerosis, experts envisioned a paradigm shift toward genetically guided treatment selection, with the potential to enhance efficacy and reduce adverse events. These insights point to a growing clinical demand for PGx-enabled molecular diagnostics in neurological care a development reflecting the broader trend of sequencing-based precision diagnostics being adopted beyond traditional therapeutic boundaries.

Overall, the innovation landscape in the molecular diagnostics in pharmacogenomics industry reflects a shift toward faster, more accessible, and clinically actionable testing solutions. The integration of advanced technologies such as AI, point-of-care systems, and multi-omics platforms is expanding the utility of PGx diagnostics beyond traditional hospital settings, supporting broader adoption across diverse therapeutic areas.

Global Molecular Diagnostics In Pharmacogenomics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global molecular diagnostics in pharmacogenomics market report based on the product, therapeutic area, technology, and region:

Product Outlook (Revenue, USD Million, 2021 - 2033)
Kits and assays
Reagents
Services
Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
Oncology
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Others
Neurological Disorders
Cardiovascular Disease
Immunological Disorders
Infectious Diseases
Others
Technology Outlook (Revenue, USD Million, 2021 - 2033)
PCR
Microarray
Sequencing
Others
Regional Outlook (Revenue, USD Million, 2021- 2030)
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Product Code: GVR-4-68040-697-1

Chapter 1. Methodology and Scope

1.1. Market Segmentation
- 1.1.1. Market Definitions
1.2. Objectives
- 1.2.1. Objective - 1
- 1.2.2. Objective - 2
- 1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
1.5. Information or Data Analysis
- 1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
- 3.4.1. Rising Demand for Personalized Medicine
- 3.4.2. Integration of NGS-Based Diagnostics in Clinical Workflows
- 3.4.3. Expanding Regulatory Support and Reimbursement Frameworks
3.5. Market Restraint Analysis
- 3.5.1. Limited Awareness Among Healthcare Providers and Patients
- 3.5.2. Cost-Related Challenges and Reimbursement Variability
3.6. Business Environment Analysis
- 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
- 3.6.2. Porter's Five Forces Analysis
- 3.6.3. Covid-19 Impact Analysis

Chapter 4. Product Business Analysis

4.1. Molecular Diagnostics in Pharmacogenomics Market: Product Movement Analysis
4.2. Kits and Assays
- 4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3. Reagents
- 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Services
- 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Therapeutic Area Business Analysis

5.1. Molecular Diagnostics in Pharmacogenomics Market: Therapeutic Area Movement Analysis
5.2. Oncology
- 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.2.2. Lung Cancer
  - 5.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.2.3. Breast Cancer
  - 5.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.2.4. Colorectal Cancer
  - 5.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.2.5. Cervical Cancer
  - 5.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.2.6. Others
  - 5.2.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.3. Neurological Disorders
- 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Cardiovascular Disease
- 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Immunological Disorders
- 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Infectious Diseases
- 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Others
- 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Technology Business Analysis

6.1. Molecular Diagnostics in Pharmacogenomics Market: Technology Movement Analysis
6.2. PCR
- 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3. Microarray
- 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. Sequencing
- 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Others
- 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Regional Business Analysis

7.1. Molecular Diagnostics in Pharmacogenomics Market Share, By Region, 2023 & 2030
7.2. North America
- 7.2.1. North America Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. Key Country Dynamics
  - 7.2.2.2. Target Disease Prevalence
  - 7.2.2.3. Competitive Scenario
  - 7.2.2.4. Regulatory Framework
  - 7.2.2.5. Reimbursement Scenario
  - 7.2.2.6. U.S. Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.2.3. Canada
  - 7.2.3.1. Key Country Dynamics
  - 7.2.3.2. Target Disease Prevalence
  - 7.2.3.3. Competitive Scenario
  - 7.2.3.4. Regulatory Framework
  - 7.2.3.5. Reimbursement Scenario
  - 7.2.3.6. Canada Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.2.4. Mexico
  - 7.2.4.1. Key Country Dynamics
  - 7.2.4.2. Target Disease Prevalence
  - 7.2.4.3. Competitive Scenario
  - 7.2.4.4. Regulatory Framework
  - 7.2.4.5. Reimbursement Scenario
  - 7.2.4.6. Mexico Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
7.3. Europe
- 7.3.1. Europe Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.3.2. Germany
  - 7.3.2.1. Key Country Dynamics
  - 7.3.2.2. Target Disease Prevalence
  - 7.3.2.3. Competitive Scenario
  - 7.3.2.4. Regulatory Framework
  - 7.3.2.5. Reimbursement Scenario
  - 7.3.2.6. Germany Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.3.3. UK
  - 7.3.3.1. Key Country Dynamics
  - 7.3.3.2. Target Disease Prevalence
  - 7.3.3.3. Competitive Scenario
  - 7.3.3.4. Regulatory Framework
  - 7.3.3.5. Reimbursement Scenario
  - 7.3.3.6. UK Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.3.4. France
  - 7.3.4.1. Key Country Dynamics
  - 7.3.4.2. Target Disease Prevalence
  - 7.3.4.3. Competitive Scenario
  - 7.3.4.4. Regulatory Framework
  - 7.3.4.5. Reimbursement Scenario
  - 7.3.4.6. France Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.3.5. Italy
  - 7.3.5.1. Key Country Dynamics
  - 7.3.5.2. Target Disease Prevalence
  - 7.3.5.3. Competitive Scenario
  - 7.3.5.4. Regulatory Framework
  - 7.3.5.5. Reimbursement Scenario
  - 7.3.5.6. Italy Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.3.6. Spain
  - 7.3.6.1. Key Country Dynamics
  - 7.3.6.2. Target Disease Prevalence
  - 7.3.6.3. Competitive Scenario
  - 7.3.6.4. Regulatory Framework
  - 7.3.6.5. Reimbursement Scenario
  - 7.3.6.6. Spain Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.3.7. Denmark
  - 7.3.7.1. Key Country Dynamics
  - 7.3.7.2. Target Disease Prevalence
  - 7.3.7.3. Competitive Scenario
  - 7.3.7.4. Regulatory Framework
  - 7.3.7.5. Reimbursement Scenario
  - 7.3.7.6. Denmark Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.3.8. Sweden
  - 7.3.8.1. Key Country Dynamics
  - 7.3.8.2. Target Disease Prevalence
  - 7.3.8.3. Competitive Scenario
  - 7.3.8.4. Regulatory Framework
  - 7.3.8.5. Reimbursement Scenario
  - 7.3.8.6. Sweden Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.3.9. Norway
  - 7.3.9.1. Key Country Dynamics
  - 7.3.9.2. Target Disease Prevalence
  - 7.3.9.3. Competitive Scenario
  - 7.3.9.4. Regulatory Framework
  - 7.3.9.5. Reimbursement Scenario
  - 7.3.9.6. Norway Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.4.2. Japan
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Target Disease Prevalence
  - 7.4.2.3. Competitive Scenario
  - 7.4.2.4. Regulatory Framework
  - 7.4.2.5. Reimbursement Scenario
  - 7.4.2.6. Japan Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.4.3. China
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Target Disease Prevalence
  - 7.4.3.3. Competitive Scenario
  - 7.4.3.4. Regulatory Framework
  - 7.4.3.5. Reimbursement Scenario
  - 7.4.3.6. China Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.4.4. India
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Target Disease Prevalence
  - 7.4.4.3. Competitive Scenario
  - 7.4.4.4. Regulatory Framework
  - 7.4.4.5. Reimbursement Scenario
  - 7.4.4.6. India Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.4.5. South Korea
  - 7.4.5.1. Key Country Dynamics
  - 7.4.5.2. Target Disease Prevalence
  - 7.4.5.3. Competitive Scenario
  - 7.4.5.4. Regulatory Framework
  - 7.4.5.5. Reimbursement Scenario
  - 7.4.5.6. South Korea Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.4.6. Australia
  - 7.4.6.1. Key Country Dynamics
  - 7.4.6.2. Target Disease Prevalence
  - 7.4.6.3. Competitive Scenario
  - 7.4.6.4. Regulatory Framework
  - 7.4.6.5. Reimbursement Scenario
  - 7.4.6.6. Australia Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.4.7. Thailand
  - 7.4.7.1. Key Country Dynamics
  - 7.4.7.2. Target Disease Prevalence
  - 7.4.7.3. Competitive Scenario
  - 7.4.7.4. Regulatory Framework
  - 7.4.7.5. Reimbursement Scenario
  - 7.4.7.6. Thailand Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
7.5. Latin America
- 7.5.1. Latin America Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Target Disease Prevalence
  - 7.5.2.3. Competitive Scenario
  - 7.5.2.4. Regulatory Framework
  - 7.5.2.5. Reimbursement Scenario
  - 7.5.2.6. Brazil Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.5.3. Argentina
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Target Disease Prevalence
  - 7.5.3.3. Competitive Scenario
  - 7.5.3.4. Regulatory Framework
  - 7.5.3.5. Reimbursement Scenario
  - 7.5.3.6. Argentina Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
7.6. MEA
- 7.6.1. MEA Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.6.2. South Africa
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Target Disease Prevalence
  - 7.6.2.3. Competitive Scenario
  - 7.6.2.4. Regulatory Framework
  - 7.6.2.5. Reimbursement Scenario
  - 7.6.2.6. South Africa Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.6.3. Saudi Arabia
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Target Disease Prevalence
  - 7.6.3.3. Competitive Scenario
  - 7.6.3.4. Regulatory Framework
  - 7.6.3.5. Reimbursement Scenario
  - 7.6.3.6. Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.6.4. UAE
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Target Disease Prevalence
  - 7.6.4.3. Competitive Scenario
  - 7.6.4.4. Regulatory Framework
  - 7.6.4.5. Reimbursement Scenario
  - 7.6.4.6. UAE Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
- 7.6.5. Kuwait
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Target Disease Prevalence
  - 7.6.5.3. Competitive Scenario
  - 7.6.5.4. Regulatory Framework
  - 7.6.5.5. Reimbursement Scenario
  - 7.6.5.6. Kuwait Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant's Overview
8.2. Financial Performance
8.3. Participant Categorization
- 8.3.1. Market Leaders
- 8.3.2. Molecular Diagnostics in Pharmacogenomics Market Share Analysis, 2023
- 8.3.3. Company Profiles
  - 8.3.3.1. Roche Diagnostics
    - 8.3.3.1.1. Company Overview
    - 8.3.3.1.2. Financial Performance
    - 8.3.3.1.3. Product Benchmarking
    - 8.3.3.1.4. Strategic Initiatives
  - 8.3.3.2. QIAGEN
    - 8.3.3.2.1. Company Overview
    - 8.3.3.2.2. Financial Performance
    - 8.3.3.2.3. Product Benchmarking
    - 8.3.3.2.4. Strategic Initiatives
  - 8.3.3.3. Thermo Fisher Scientific
    - 8.3.3.3.1. Company Overview
    - 8.3.3.3.2. Financial Performance
    - 8.3.3.3.3. Product Benchmarking
    - 8.3.3.3.4. Strategic Initiatives
  - 8.3.3.4. Illumina, Inc.
    - 8.3.3.4.1. Company Overview
    - 8.3.3.4.2. Financial Performance
    - 8.3.3.4.3. Product Benchmarking
    - 8.3.3.4.4. Strategic Initiatives
  - 8.3.3.5. Agilent Technologies
    - 8.3.3.5.1. Company Overview
    - 8.3.3.5.2. Financial Performance
    - 8.3.3.5.3. Product Benchmarking
    - 8.3.3.5.4. Strategic Initiatives
  - 8.3.3.6. Abbott Molecular
    - 8.3.3.6.1. Company Overview
    - 8.3.3.6.2. Financial Performance
    - 8.3.3.6.3. Product Benchmarking
    - 8.3.3.6.4. Strategic Initiatives
  - 8.3.3.7. Genomind
    - 8.3.3.7.1. Company Overview
    - 8.3.3.7.2. Financial Performance
    - 8.3.3.7.3. Product Benchmarking
    - 8.3.3.7.4. Strategic Initiatives
  - 8.3.3.8. OneOme
    - 8.3.3.8.1. Company Overview
    - 8.3.3.8.2. Financial Performance
    - 8.3.3.8.3. Product Benchmarking
    - 8.3.3.8.4. Strategic Initiatives
  - 8.3.3.9. Myriad Genetics
    - 8.3.3.9.1. Company Overview
    - 8.3.3.9.2. Financial Performance
    - 8.3.3.9.3. Product Benchmarking
    - 8.3.3.9.4. Strategic Initiatives
  - 8.3.3.10. Invitae (formerly YouScript)
    - 8.3.3.10.1. Company Overview
    - 8.3.3.10.2. Financial Performance
    - 8.3.3.10.3. Product Benchmarking
    - 8.3.3.10.4. Strategic Initiatives

Product Code: GVR-4-68040-697-1

List of Tables

Table 1 Molecular Diagnostics in Pharmacogenomics Market - Industry Snapshot & Key Buying Criteria, 2021 - 2033
Table 2 Global Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 3 Global Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 4 Global Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 5 Global Molecular Diagnostics in Pharmacogenomics Market, by region, 2021 - 2033 (USD Million)
Table 6 Molecular Diagnostics in Pharmacogenomics- Key market driver analysis
Table 7 Molecular Diagnostics in Pharmacogenomics- Key market restraint analysis
Table 8 North America Molecular Diagnostics in Pharmacogenomics Market, by country, 2021 - 2033 (USD Million)
Table 9 North America Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 10 North America Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 11 North America Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 12 U.S. Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 13 U.S. Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 14 U.S. Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 15 Canada Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 16 Canada Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 17 Canada Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 18 Mexico Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 19 Mexico Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 20 Mexico Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 21 Europe Molecular Diagnostics in Pharmacogenomics Market, by country, 2021 - 2033 (USD Million)
Table 22 Europe Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 23 Europe Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 24 Europe Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 25 Germany Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 26 Germany Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 27 Germany Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 28 UK Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 29 UK Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 30 UK Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 31 France Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 32 France Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 33 France Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 34 Italy Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 35 Italy Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 36 Italy Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 37 Spain Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 38 Spain Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 39 Spain Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 40 Denmark Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 41 Denmark Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 42 Denmark Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 43 Sweden Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 44 Sweden Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 45 Sweden Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 46 Norway Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 47 Norway Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 48 Norway Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 49 Asia Pacific Molecular Diagnostics in Pharmacogenomics Market, by country, 2021 - 2033 (USD Million)
Table 50 Asia Pacific Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 51 Asia Pacific Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 52 Asia Pacific Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 53 Japan Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 54 Japan Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 55 Japan Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 56 China Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 57 China Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 58 China Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 59 India Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 60 India Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 61 India Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 62 Australia Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 63 Australia Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 64 Australia Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 65 South Korea Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 66 South Korea Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 67 South Korea Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 68 Thailand Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 69 Thailand Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 70 Thailand Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 71 Latin America Molecular Diagnostics in Pharmacogenomics Market, by country, 2021 - 2033 (USD Million)
Table 72 Latin America Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 73 Latin America Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 74 Latin America Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 75 Brazil Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 76 Brazil Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 77 Brazil Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 78 Argentina Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 79 Argentina Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 80 Argentina Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 81 MEA Molecular Diagnostics in Pharmacogenomics Market, by country, 2021 - 2033 (USD Million)
Table 82 MEA Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 83 MEA Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 84 MEA Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 85 South Africa Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 86 South Africa Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 87 South Africa Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 88 Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 89 Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 90 Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 91 UAE Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 92 UAE Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 93 UAE Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
Table 94 Kuwait Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
Table 95 Kuwait Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
Table 96 Kuwait Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area

List of Figures

Fig. 1 Molecular Diagnostics in Pharmacogenomics Market Segmentation
Fig. 2 Global Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 3 Molecular Diagnostics in Pharmacogenomics Market Dynamics
Fig. 4 Key Opportunities Prioritized, 2021
Fig. 5 Molecular Diagnostics in Pharmacogenomics Market - Porter's Analysis
Fig. 6 Molecular Diagnostics in Pharmacogenomics Market - PESTEL Analysis
Fig. 7 Molecular Diagnostics in Pharmacogenomics Revenue Share, By Product, 2023 & 2030
Fig. 8 Kits and assays Market, 2021 - 2033 (USD Million)
Fig. 9 Reagents Market, 2021 - 2033 (USD Million)
Fig. 10 Services Market, 2021 - 2033 (USD Million)
Fig. 11 Molecular Diagnostics in Pharmacogenomics Revenue Share, By Technology, 2023 & 2030
Fig. 12 PCR Market, 2021 - 2033 (USD Million)
Fig. 13 Microarray Market, 2021 - 2033 (USD Million)
Fig. 14 Sequencing Market, 2021 - 2033 (USD Million)
Fig. 15 Others Market, 2021 - 2033 (USD Million)
Fig. 16 Molecular Diagnostics in Pharmacogenomics Revenue Share, By Therapeutic Area, 2023 & 2030
Fig. 17 Oncology Market, 2021 - 2033 (USD Million)
Fig. 18 Lung Cancer Market, 2021 - 2033 (USD Million)
Fig. 19 Breast Cancer Market, 2021 - 2033 (USD Million)
Fig. 20 Colorectal Cancer Market, 2021 - 2033 (USD Million)
Fig. 21 Cervical Cancer Market, 2021 - 2033 (USD Million)
Fig. 22 Others Market, 2021 - 2033 (USD Million)
Fig. 23 Neurological Disorders Market, 2021 - 2033 (USD Million)
Fig. 24 Cardiovascular Disease Market, 2021 - 2033 (USD Million)
Fig. 25 Immunological Disorders Market, 2021 - 2033 (USD Million)
Fig. 26 Infectious Diseases Market, 2021 - 2033 (USD Million)
Fig. 27 Others Market, 2021 - 2033 (USD Million)
Fig. 28 Molecular Diagnostics in Pharmacogenomics Revenue Share, By Region, 2023 & 2030
Fig. 29 North America Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 30 US Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 31 Canada Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 32 Mexico Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 33 Europe Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 34 Germany Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 35 UK Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 36 France Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 37 Italy Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 38 Spain Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 39 Denmark Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 40 Sweden Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 41 Norway Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 42 Asia Pacific Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 43 Japan Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 44 China Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 45 India Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 46 Australia Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 47 South Korea Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 48 Thailand Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 49 Latin America Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 50 Brazil Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 51 Argentina Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 52 MEA Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 53 South Africa Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 54 Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 55 UAE Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
Fig. 56 Kuwait Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)

Molecular Diagnostics In Pharmacogenomics Market Size, Share & Trends Analysis Report By Product (Kits & Assays, Reagents, Services), By Therapeutic Area, By Technology, By Region, And Segment Forecasts, 2025 - 2033

Description

Table of Contents

List of Tables

Molecular Diagnostics In Pharmacogenomics Market Summary

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. Product Business Analysis

Chapter 5. Therapeutic Area Business Analysis

Chapter 6. Technology Business Analysis

Chapter 7. Regional Business Analysis

Chapter 8. Competitive Landscape

List of Tables

List of Figures